Home / Companies / Royalty Pharma Plc / 6 Jun 2024
Royalty Pharma Plc: meeting of 6 Jun 2024
Votes reported on Form N-PX, item by item
568 Form N-PX filers reported votes at the Royalty Pharma Plc meeting of 6 Jun 2024. Their records fall into 8 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
DIRECTOR ELECTIONSIssuer
Director elections
8 nominees; 93.5% of reported votes for; 48 filers withheld from or voted against at least one nominee.
3,161 vote records from 181 filers. 2 of the 180 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
SECTION 14A SAY-ON-PAY VOTESIssuer
Advisory vote on executive pay (say-on-pay)
1,034 vote records from 560 filers. 137 of the 539 filers that marked the item either way voted against management. 21 filers reported this item without a management mark.
AUDIT-RELATEDIssuer
Audit-related items (auditor ratification)
1,190 vote records from 181 filers. 2 of the 180 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
CAPITAL STRUCTUREIssuer
CAPITAL STRUCTURE: management items
Management items in this category are shown together; filers word and number them differently.
780 vote records from 177 filers. 2 of the 176 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
COMPENSATIONIssuer
COMPENSATION: management items
Management items in this category are shown together; filers word and number them differently.
788 vote records from 200 filers. 36 of the 198 filers that marked the item either way voted against management. 2 filers reported this item without a management mark.
CORPORATE GOVERNANCEIssuer
CORPORATE GOVERNANCE: management items
Management items in this category are shown together; filers word and number them differently.
344 vote records from 154 filers. 1 of the 153 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
OTHERIssuer
OTHER: management items
Management items in this category are shown together; filers word and number them differently.
51 vote records from 28 filers. 0 of the 28 filers that marked the item either way voted against management.
Several categoriesSecurity holder
Shareholder proposals (not separable from the filings)
Filers described these proposals in wordings that could not be matched to one another, so they are shown together.
1 vote records from 1 filers. 0 of the 1 filers that marked the item either way voted against management.
How the largest families voted
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the Royalty Pharma Plc meeting?
568 Form N-PX filers reported votes at the meeting of 6 Jun 2024. On say-on-pay, 137 of 539 voted against management (25.4%). The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Royalty Pharma Plc on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Royalty Pharma Plc
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Royalty Pharma Plc with a meeting date within three days of 6 Jun 2024. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.